Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1

References

  1. Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ. Patient reports of complications of bone marrow transplantation. Support Care Cancer. 2000;8:33–9.

    CAS  PubMed  Google Scholar 

  2. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100:1995–2025.

    Article  Google Scholar 

  3. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590–8.

    CAS  Article  Google Scholar 

  4. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19:2201–5.

    CAS  Article  Google Scholar 

  5. Finch PW, Mark Cross LJ, McAuley DF, Farrell CL. Palifermin for the protection and regeneration of epithelial tissues following injury: new findings in basic research and pre-clinical models. J Cell Mol Med. 2013;17:1065–87.

    CAS  Article  Google Scholar 

  6. Vadhan-Raj S, Goldberg JD, Perales MA, Berger DP, van den Brink MR. Clinical applications of palifermin: amelioration of oral mucositis and other potential indications. J Cell Mol Med. 2013;17:1371–84.

    CAS  Article  Google Scholar 

  7. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820–31.

    CAS  Article  Google Scholar 

  8. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979.

    Google Scholar 

  9. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.

    CAS  PubMed  Google Scholar 

  10. Langner S, Staber P, Schub N, Gramatzki M, Grothe W, Behre G, et al. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant. 2008;42:275–9.

    CAS  Article  Google Scholar 

  11. Goldberg JD, Zheng J, Castro-Malaspina H, Jakubowski AA, Heller G, van den Brink MR, et al. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant. 2013;48:99–104.

    CAS  Article  Google Scholar 

  12. Jagasia MH, Abonour R, Long GD, Bolwell BJ, Laport GG, Shore TB, et al. Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial. Bone Marrow Transplant. 2012;47:1350–5.

    CAS  Article  Google Scholar 

  13. Verhagen MP, Wondergem MJ, Visser O. Palifermin dose should be adjusted to different therapy regimens. Bone Marrow Transplant. 2009;43:665.

    CAS  Article  Google Scholar 

  14. Gibson RJ, Keefe DM, Clarke JM, Regester GO, Thompson FM, Goland GJ, et al. The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol. 2002;50:53–8.

    CAS  Article  Google Scholar 

  15. van der Velden WJ, Herbers AH, Blijlevens NM. Palifermin in allogeneic HSCT: many questions remain. Bone Marrow Transplant. 2009;43:85–6.

    Article  Google Scholar 

Download references

Acknowledgements

The study was conducted in cooperation with the Eastern German Study Group of Haematology and Oncology (OSHO, protocol code OSHO #76). Palifermin (Kepivance®) was provided by Swedish Orphan Biovitrum AB (Sobi), SE-112 76 Stockholm, Sweden. We further thank GMIHO (Gesellschaft für medizinische Innovation/Hämatologie und Onkologie mbH, Berlin, Germany) for the technical support of this trial, and Dr. Andreas Engelen (WiSP—Wissenschaftlicher Service Pharma GmbH, Langenfeld, Germany) for data monitoring and biostatistics.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Herbert G. Sayer.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Support: Palifermin was provided by Swedish Orphan Biovitrum

EudraCT database: 2006-003683-54.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Schmidt, V., Niederwieser, D., Schenk, T. et al. Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 53, 1188–1192 (2018). https://doi.org/10.1038/s41409-018-0135-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0135-3

Further reading

Search

Quick links